| 2002 |
Eriksen E, Melsen F, Sod E, Barton I, Chines A. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone. November 2002;31(5):620-625. |
27 |
23 |
| 2004 |
Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone. April 2004;34(4):736-746. |
34 |
33 |
| 2020 |
Ferrari S, Eastell R, Napoli N, Schwartz A, Hofbauer LC, Chines A, Wang A, Pannacciulli N, Cummings SR. Denosumab in postmenopausal women with osteoporosis and diabetes: subgroup analysis of FREEDOM and FREEDOM extension. Bone. May 2020;134:115268. |
2 |
0 |
| 2022 |
Hu YJ, Chines A, Shi Y, Seeman E, Guo XE. The effect of denosumab and alendronate on trabecular plate and rod microstructure at the distal tibia and radius: a post-hoc HR-pQCT study. Bone. January 2022;154:116187. |
1 |
1 |
| 2003 |
Eastell R, Barton I, Hannon R, Chines A, Garnero P, Delmas P. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. June 2003;18(6):1051-1056. |
28 |
23 |
| 2020 |
Chotiyarnwong P, McCloskey E, Eastell R, McClung MR, Gielen E, Gostage J, McDermott M, Chines A, Huang S, Cummings SR. A pooled analysis of fall incidence from placebo‐controlled trials of denosumab. J Bone Miner Res. June 2020;35(6):1014-1021. |
1 |
1 |
| 2020 |
Dempster DW, Chines A, Bostrom MP, Nieves JW, Zhou H, Chen L, Pannacciulli N, Wagman RB, Cosman F. Modeling‐based bone formation in the human femoral neck in subjects treated with denosumab. J Bone Miner Res. July 2020;35(7):1282-1288. |
2 |
1 |
| 2021 |
Eastell R, Black DM, Lui L, Chines A, Marin F, Khosla S, de Papp AE, Cauley JA, Mitlak B, McCulloch CE, Vittinghoff E, Bauer DC; Foundation for the National Institutes of Health (FNIH) Bone Quality Project. Treatment‐related changes in bone turnover and fracture risk reduction in clinical trials of antiresorptive drugs: proportion of treatment effect explained. J Bone Miner Res. February 2021;36(2):236-243. |
0 |
0 |
| 2022 |
Eastell R, Vittinghoff E, Lui L-Y, McCulloch CE, Pavo I, Chines A, Khosla S, Cauley JA, Mitlak B, Bauer DC, Bouxsein M, Black DM. Validation of the surrogate threshold effect for change in bone mineral density as a surrogate endpoint for fracture outcomes: the FNIH-ASBMR SABRE project. J Bone Miner Res. January 2022;37(1):29-35. |
5 |
3 |
| 2022 |
Farlay D, Rizzo S, Dempster DW, Huang S, Chines A, Brown JP, Boivin G. Bone mineral and organic properties in postmenopausal women treated with denosumab for up to 10 years. J Bone Miner Res. May 2022;37(5):856-864. |
1 |
1 |
| 2022 |
Geusens P, Bevers MSAM, van Rietbergen B, Messina OD, Lespessailles E, Oliveri B, Chapurlat R, Engelke K, Chines A, Huang S, Saag KG, van den Bergh JP. Effect of denosumab compared with risedronate on bone strength in patients initiating or continuing glucocorticoid treatment. J Bone Miner Res. June 2022;37(6):1136-1146. |
0 |
0 |
| 2022 |
Miller PD, Adachi JD, Albergaria B-H, Cheung AM, Chines AA, Gielen E, Langdahl BL, Miyauchi A, Oates M, Reid IR, Santiago NR, Vanderkelen M, Wang Z, Yu Z. Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Res. August 2022;37(8):1437-1445. |
4 |
3 |
| 2020 |
Miller PD, Pannacciulli N, Malouf-Sierra J, Singer A, Czerwiński E, Bone HG, Wang C, Huang S, Chines A, Lems W, Brown JP. Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates. Osteoporos Int. January 2020;31(1):181-191. |
0 |
0 |